Early Disease Detection Venture
Mayo Clinic and Thermo Fisher Launch Venture to Predict Disease Years Early
Anonymous
Mayo Clinic and Thermo Fisher Scientific have launched Precure LLC, a joint venture aimed at identifying biological signals of disease years before symptoms appear. The company plans to build a large biomedical dataset linking genomic, proteomic and longitudinal clinical information from about 1 million biospecimens, using artificial intelligence and large-scale analytics. Mayo will be the majority owner and contribute clinical data and AI expertise, while Thermo Fisher will provide scientific technology and proteomics infrastructure. The initiative is intended to support earlier diagnosis, more targeted therapies and faster drug development for conditions including cancer, cardiometabolic disease, neurological disorders and immune-mediated diseases. Mayo said any financial returns will be reinvested in its nonprofit patient-care, research and education programs.
Key Points
1
Precure LLC will operate alongside Mayo Clinic’s existing Precure Research initiative, providing the scale, infrastructure and collaborations needed to turn early-disease findings into diagnostics, therapies and other health-care solutions.
2
The planned dataset will link molecular information from one million biospecimens with longitudinal clinical records collected over several years, allowing researchers to track biological changes as people move from health toward disease.
3
Mayo said the initiative will integrate the genomic and proteomic information with its clinical data and expertise in a highly standardized setting, with AI and large-scale analytics used to identify patterns in the complex dataset.
4
Thermo Fisher CEO Marc Casper said the partnership could create “new opportunities at unprecedented scale” to detect disease earlier, accelerate drug development and enable more precise therapies.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
7
Articles
6
Reach
13
Topics
A
AnonymousAuthor
